New therapies, new concerns: rituximab-associated lung injury.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease.Frontiers in pharmacology · 2023
   Article
2. Translational cancer research · 2022
   Article
3. Exploration and Evaluation of Therapeutic Efficacy of Drug-Free Macromolecular Therapeutics in Collagen-Induced Rheumatoid Arthritis Mouse Model.Macromolecular bioscience · 2020
   Article
4. Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.Journal of controlled release : official journal of the Controlled Release Society · 2017
   Article
5. Design of smart HPMA copolymer-based nanomedicines.Journal of controlled release : official journal of the Controlled Release Society · 2016
   Review
6. Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.Biomaterials science · 2015
   Article
7. Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis.ACS nano · 2014
   Article
8. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis.Biomaterials · 2012
   Article
9. Treatment of steroid-resistant pediatric nephrotic syndrome.Korean journal of pediatrics · 2011
   Article
10. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.Clinical journal of the American Society of Nephrology : CJASN · 2010
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as